Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
—
—
—
The Company offer various pharmaceutical formulations such as tablets, capsules, syrups, suspension and powders, focusing on segments such as ANTIBIOTICS, COUGH/COLD/ALLERGY, H-1RECEPTOR ANTAGONIST (ANTIULCERANT), NUTRACEUTICALS and NSAIDS
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has almost stayed constant
BIJOY HANS LTD. - 524723 - Board Meeting Intimation for 1. To Consider, Approve And Take On Record The Unaudited Financial Results Of The Company For The Quarter Ended 31St December, 2024. 2. Any Other Matter With The Permission Of The Chair. | Download
BIJOY HANS LTD. - 524723 - Board Meeting Intimation for 1. To Consider, Approve And Take On Record The Unaudited Financial Results Of The Company For The Quarter Ended 31St December, 2024. 2. Any Other Matter With The Permission Of The Chair. | Download
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant